


**Product Name** : Lorlatinib  
**Cat. No.** : PC-42919  
**CAS No.** : 1454846-35-5  
**Molecular Formula** : C<sub>21</sub>H<sub>19</sub>FN<sub>6</sub>O<sub>2</sub>  
**Molecular Weight** : 406.413  
**Target** : Anaplastic Lymphoma Kinase (ALK)  
**Solubility** : DMSO: ≥ 28 mg/mL



## Biological Activity

A novel CNS-penetrant, ATP-competitive inhibitor of ALK/ROS1 with IC<sub>50</sub> of 0.07/0.025 nM respectively; also inhibits ALK L1196M (IC<sub>50</sub>=0.7 nM) and exhibits selectivity >100-fold for ROS1 over 204 kinases; inhibits crizotinib-resistant mutant ROS1G2032R and ROS1L2026M and orally available in vivo.

Lung Cancer  
Phase 3 Clinical

## References

Zou HY, et al. Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):3493-8.

Johnson TW, et al. J Med Chem. 2014 Jun 12;57(11):4720-44.

Infarinato NR, et al. Cancer Discov. 2016 Jan;6(1):96-107.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com